Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach remain controversial, posing a significant challenge for clinicians. The current standard of care for metastatic disease is to start systemic therapy; however, active surveillance and targeted radiotherapy have become attractive options to mitigate the long-term effects of androgen deprivation therapy (ADT). Furthermore, evolving biomarker methodologies may further define optimal treatment selection. In this review, we summarize the current understanding that guides the treatment of OMPC, with a focus on how host response can be an important contributing factor. Evolving scientific understanding and clinical development will continue to shape the landscape of treatment strategies for this distinct disease state.
寡转移性前列腺癌（OMPC）是指前列腺癌从局部进展至广泛转移过程中的一种中间状态，其影像学上显著的转移灶在数量和位置上均较为有限。由于目前缺乏明确的定义共识，其诊断意义及相应的最佳治疗方案仍存在争议，这给临床医生带来了重大挑战。目前转移性前列腺癌的标准治疗是启动全身性治疗；然而，主动监测和靶向放疗已成为减轻雄激素剥夺治疗（ADT）长期影响的有吸引力的选择。此外，不断发展的生物标志物检测方法可能进一步明确最佳治疗选择。本文综述了当前指导OMPC治疗的认识，重点关注宿主反应如何成为重要的影响因素。不断发展的科学认知和临床进展将继续塑造这一独特疾病状态的治疗策略格局。
肿瘤(癌症)患者之家